Occurrence and risk of cochleotoxicity in cystic fibrosis patients receiving repeated high-dose aminoglycoside therapy

Antimicrobial Agents and Chemotherapy

Volumn 45, Issue 9, 2001, Pages 2502-2509

  Mulheran, M ^a   Degg, C ^a   Burr, S ^a   Morgan, D W ^a   Stableforth, D E ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; GENTAMICIN; TOBRAMYCIN;

ADOLESCENT; ADULT; ANTIBIOTIC THERAPY; ARTICLE; AUDITORY THRESHOLD; CONTROLLED STUDY; CYSTIC FIBROSIS; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG MEGADOSE; EAR PROTECTION; HEARING LOSS; HUMAN; INCIDENCE; INNER EAR DISEASE; MAJOR CLINICAL STUDY; OTOTOXICITY; PRIORITY JOURNAL; PURE TONE AUDIOMETRY; RISK; SCHOOL CHILD;

ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; AUDIOMETRY, PURE-TONE; CHILD; CYSTIC FIBROSIS; DEAFNESS; DRUG THERAPY, COMBINATION; DRUG UTILIZATION; GENTAMICINS; HEARING; HUMANS; OVERDOSE; RADIO WAVES; TOBRAMYCIN;

EID: 0034862969     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.45.9.2502-2509.2001     Document Type: Article

References (46)

1. Current perspectives on inner ear toxicity
2. Aminoglycoside toxicity and relation to dose regimen
3. Ototoxicity: Clinical considerations and comparative information
4. Recommended procedures for pure tone audiometry using a manually operated instrument
5. Recommended procedures for pure tone bone conduction audiometry without masking using a manually operated instrument
6. Recommendations for masking in pure tone threshold audiometry
7. Recommended procedure for tympanometry
8. Drug-induced ototoxicity
9. A survey of prospective controlled clinical trials of gentamicin, tobramycin, amikacin, and netilmicin
10. Intensive treatment of Pseudomonas chest infection in cystic fibrosis: A comparison of tobramycin and ticarcillin and netilmicin and ticarcillin
11. Activation of aminoglycoside antibiotics to cytotoxins
12. Ototoxicity of aminoglycoside antibiotics in long-term treatment for cystic fibrosis
13. Antibiotic pharmacokinetics in cystic fibrosis: Differences and clinical significance
14. Pharmacokinetics of gentamicin in the sensory cells of organ of Corti: Rapid uptake and long-term persistence
15. Improving audiometric thresholds by changing the headphone position at the ear
16. Pulmonary infection in cystic fibrosis
17. Aminoglycoside-induced ototoxicity
18. Gentamicin uptake by cochlear hair cells precedes hearing impairment during chronic treatment
19. Acoustics - Thresholds of hearing by air conduction as a function of age and sex for otologically normal persons
20. Ototoxicity of gentamicin in man: A survey and controlled analysis of clinical experience in the United States
21. Changes in cochlear antioxidant enzyme activity after sound conditioning and noise exposure in the chinchilla
22. Aminoglycoside ototoxicity - A review of clinical studies published between 1975 and 1982
23. Contralateral suppression of distortion product otoacoustic emissions in children with cystic fibrosis: Effects of tobramycin
24. Aminoglycoside ototoxicity
25. The distribution of hearing thresholds in the general population aged 18-30 years
26. Tobramycin therapy of infection due to Pseudomonas aeruginosa in patients with cystic fibrosis: Effects of dosage and concentration in sputum
27. Risk factors in the development of auditory toxicity in patients receiving aminoglycosides
28. Comparison of distortion product OAE generation between a patient group requiring frequent gentamicin therapy and control subjects
29. Aminoglycoside-induced ototoxicity in patients with cystic fibrosis
30. Ototoxicity of tobramycin: A clinical overview
31. Prospective studies of the ototoxicity of gentamicin
32. Cumulative and acute toxicity of repeated high-dose tobramycin in cystic fibrosis
33. Evaluation of a high dose tobramycin and ticarcillin treatment protocol in cystic fibrosis based on improved susceptibility criteria and antibiotic pharmacokinetics
34. Threshold of hearing as a function of age and sex for the typical unscreened population
35. Cystic fibrosis in the adolescent and adult
36. Antioxidants attenuate gentamicin-induced free radical formation in vitro and ototoxicity in vivo: D-methionine is a potential protectant
37. Stimulation of free radical formation by aminoglycoside antibiotics
38. Minimisation of aminoglycoside toxicity in patients with cystic fibrosis
39. Comparative clinical trials of aminoglycosides
40. Frequent antibiotic therapy improves the survival of CF patients with chronic Pseudomonas aeruginosa infection
41. Kinetics of gentamicin uptake and release in the rat: Comparison of inner ear tissues and fluids with other organs
42. Minimisation of aminoglycoside toxicity in patients with cystic fibrosis
43. Hypothetical framework for enhanced renal tubular secretion of drugs in cystic fibrosis